The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization

Abstract

Subconjunctival bevacizumab, ranibizumab, and aflibercept crossed the blood and seemed to be effective in inhibiting corneal neovascularization without causing epitheliopathy in an experimental rat model compared to the controls. However, no significant results were noted between these three anti-VEGF molecules.